Stocktoria
Cardio Diagnostics Holdings, Inc. CDIO
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2021-11-23
Cardio Diagnostics Holdings, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14,825 | $34,890 | $17,065 | $950 | $901 |
| R&D expense | $641,212 | $227,966 | $145,182 | $40,448 | $31,468 |
| Operating income | -$6.5M | -$8.4M | -$7.2M | -$4.5M | -$620,448 |
| Interest expense | $14,801 | $18,640 | $6.7M | — | — |
| Income tax | — | — | — | $0 | $0 |
| Net income | -$6.5M | -$8.4M | -$8.4M | -$4.7M | -$620,448 |
| EPS (diluted) | $-3.71 | $-9.35 | $-0.66 | $-1.51 | $-0.53 |
| Operating cash flow | -$5.7M | -$5.0M | -$5.7M | -$5.1M | -$585,291 |
| Free cash flow | -$5.9M | -$5.2M | -$6.2M | — | — |
| Cash & equivalents | $0 | $0 | $0 | $0 | $0 |
| Total assets | $7.8M | $10.6M | $4.5M | $6.2M | $1.1M |
| Total liabilities | $793,061 | $1.1M | $1.5M | $1.9M | $33,885 |
| Shareholders' equity | $7.0M | $9.6M | $3.0M | $4.3M | $1.1M |
Source: SEC EDGAR filings · CIK 0001870144 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.